JP2021521193A5 - - Google Patents

Info

Publication number
JP2021521193A5
JP2021521193A5 JP2020555841A JP2020555841A JP2021521193A5 JP 2021521193 A5 JP2021521193 A5 JP 2021521193A5 JP 2020555841 A JP2020555841 A JP 2020555841A JP 2020555841 A JP2020555841 A JP 2020555841A JP 2021521193 A5 JP2021521193 A5 JP 2021521193A5
Authority
JP
Japan
Prior art keywords
stem cells
equivalent
polypeptide
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027967 external-priority patent/WO2019204509A2/en
Publication of JP2021521193A publication Critical patent/JP2021521193A/ja
Publication of JP2021521193A5 publication Critical patent/JP2021521193A5/ja
Priority to JP2024196696A priority Critical patent/JP2025015574A/ja
Pending legal-status Critical Current

Links

JP2020555841A 2018-04-18 2019-04-17 虚血および心筋症の処置のための組成物および方法 Pending JP2021521193A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024196696A JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659667P 2018-04-18 2018-04-18
US62/659,667 2018-04-18
PCT/US2019/027967 WO2019204509A2 (en) 2018-04-18 2019-04-17 Compositions and methods for the treatment of ischemia and cardiomyopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024196696A Division JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021521193A JP2021521193A (ja) 2021-08-26
JP2021521193A5 true JP2021521193A5 (https=) 2022-04-06

Family

ID=68240639

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020555841A Pending JP2021521193A (ja) 2018-04-18 2019-04-17 虚血および心筋症の処置のための組成物および方法
JP2024196696A Pending JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024196696A Pending JP2025015574A (ja) 2018-04-18 2024-11-11 虚血および心筋症の処置のための組成物および方法

Country Status (5)

Country Link
US (2) US20210113662A1 (https=)
EP (2) EP3781182A4 (https=)
JP (2) JP2021521193A (https=)
IL (1) IL277773B1 (https=)
WO (1) WO2019204509A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
US6103255A (en) 1999-04-16 2000-08-15 Rutgers, The State University Porous polymer scaffolds for tissue engineering
WO2002024920A2 (en) * 2000-09-19 2002-03-28 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
IL157335A0 (en) 2001-03-13 2004-02-19 Novartis Ag Lentiviral packaging constructs
DE10132440A1 (de) 2001-07-04 2003-01-23 Bosch Gmbh Robert System und Verfahren zum Überwachen des Fahrverhaltens eines Fahrzeugs
US20050271639A1 (en) 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US6993406B1 (en) 2003-04-24 2006-01-31 Sandia Corporation Method for making a bio-compatible scaffold
ATE388223T1 (de) 2003-10-29 2008-03-15 Fcb Pharmicell Co Ltd Verfahren zur differenzierung einer mesenchym- stammzelle zu einer nervenzelle sowie die nervenzelle enthaltende pharmazeutische zusammensetzung gegen eine neurodegenerative krankheit
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
KR20070085288A (ko) * 2004-09-24 2007-08-27 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
EP2465924A3 (en) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
WO2011026041A2 (en) * 2009-08-28 2011-03-03 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
ES2610241T3 (es) * 2009-10-23 2017-04-26 Amorcyte, Inc. Composiciones y usos para el tratamiento de lesiones miocárdicas progresivas debidas a una insuficiencia vascular
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
GB201303666D0 (en) 2013-03-01 2013-04-17 Goldsborough Andrew S Sample fixation and stabilisation
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2015168145A1 (en) * 2014-04-28 2015-11-05 Penn Marc S Sdf-1 delivery for treating advanced ischemic cardiomyopathy
UA124450C2 (uk) * 2014-12-01 2021-09-22 Самма Хелт Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
EP3781182A4 (en) * 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Similar Documents

Publication Publication Date Title
CA2504019C (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
Han et al. The history and role of naturally occurring mouse models with Pde6b mutations
US8883756B2 (en) SDF-1 delivery for treating ischemic tissue
JP7374527B2 (ja) α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
ES2520044T3 (es) SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
EP1578200A1 (en) Cell-based vegf delivery
Zhou et al. Angiogenic gene‐modified myoblasts promote vascularization during repair of skeletal muscle defects
KR20140116054A (ko) 다발성 경화증의 치료를 위한 ａｐｃ-매개 관용 유도
JP2021521193A5 (https=)
Yu et al. Advances in gene therapy for erectile dysfunction: Promises and challenges
Takehara Cell therapy for cardiovascular regeneration
MacColl et al. Optimisation of growth hormone production by muscle cells using plasmid DNA
CN117683725A (zh) 人脐带间充质干细胞msc-n1及其应用
CN111909246B (zh) 高效感染支持细胞的aav突变体
Roncalli et al. Biological approaches to ischemic tissue repair: gene-and cell-based strategies
US20030148952A1 (en) Methods and materials for the recruitment of endothelial cells
Roncalli et al. Update on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure
EP3996734A1 (en) Modified cells and related methods
Farge Mesenchymal Stromal Cells for Systemic Sclerosis
AU2010241483B2 (en) Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration
WO2015168145A1 (en) Sdf-1 delivery for treating advanced ischemic cardiomyopathy
Papanikolaou et al. Novel Therapies for Heart Failure: The Gene and Cell Methods
WO2015153357A1 (en) Compositions and methods for improving cardiac function
EA041766B1 (ru) Аденовирусный вектор с модифицированным капсидом и применение его в медицине
Sharma An Evaluation of Modulating an Ischemic Environment Through Angiogenic and Stem Cell Recruitment Chemokine Supplementation in an Effort to Improve Functional Regeneration in Post-Acute Compartment Syndrome